Paternal age predicts live birth in women above 40 years of age undergoing in-vitro fertilization (IVF)

Guy Shrem\textsuperscript{1,2}, Nouf M. Alasman\textsuperscript{2}, Jacques Balayla\textsuperscript{1}, Alexander Volodarsky-Perel\textsuperscript{1,2}, Weon-Young Son\textsuperscript{2}, Michael H. Dahan\textsuperscript{1,2,}\textsuperscript{*}

\textsuperscript{1} Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill University, 845 Rue Sherbrooke O, Montréal, QC H3A 0G4, Canada
\textsuperscript{2} MUHC Reproductive Center, McGill University, 888 Boul de Maisonneuve E #200, Montréal, QC H2L 4S8, Canada

\textsuperscript{*}Correspondence: dahanhaim@hotmail.com (Michael H. Dahan)

DOI: 10.31083/j.ceog.2021.02.2275

This is an open access article under the CC BY-NC 4.0 license (https://creativecommons.org/licenses/by-nc/4.0/).

Submitted: 28 August 2020 Revised: 21 October 2020 Accepted: 20 November 2020 Published: 15 April 2021

**Purpose**: To determine which factors predict pregnancy outcome in women aged 40 years and above who underwent in-vitro fertilization.

**Method**: We conducted a retrospective case-control study of 631 women aged 40–46 years, who underwent a total of 904 IVF cycles with autologous gametes. We used stepwise logistic regression analysis to develop predictors of pregnancy, clinical pregnancy and live birth outcomes. Data are presented as mean ± SD, percentage and confidence intervals. **Results**: Predictors of live birth included maternal (95% CI: 0.36–0.78) and paternal (95% CI: 0.62–0.94) age, the number of follicles >14 mm (95% CI: 1.2–3.2), the number of oocytes collected (95% CI: 1.3–2.9) the number of metaphase II oocytes (95% CI: 1.3–2.4) and the number of cleavage stage embryos (95% CI: 1.8–2.6). The predictors of pregnancy and clinical pregnancy were similar but did not include male age (P > 0.05). To further determine the role of male age in live birth a control group of women younger than 40 years was collected. Male age was not a significant predictor of live birth among younger women (P = 0.42). **Conclusions**: Female age and better ovarian stimulation were confirmed as predictors of outcomes in older women doing IVF. However, male age was also noted to be a significant individual predictor of live birth in women over 40 years of age, but not in younger women doing IVF.

**Keywords**: Advanced maternal age, Advanced paternal age; Biologic clock; IVF; In-vitro fertilization

1. Introduction

The proportion of women postponing pregnancy beyond age 40 has greatly increased over the last decades. On average, over 50% of these women will have difficulty attempting conception [1]. According to natural fertility studies, by age 40, one-third of women will be infertile [2]. In the United States, between 2006–2010, around 15% of women aged 40–44 required artificial reproductive technologies (ART) to conceive, compared to 1.3% of women aged 15–24 years [3]. In 2016, women over 40 represented approximately 21% of the treated patients at infertility centers in the USA [4]. When undergoing IVF with their own gametes, studies have reported a live birth rate (LBR) of 12.7% per IVF cycle in women between the ages of 40–42 years, falling to 5.1% for ages 43–44 years, and decreasing further to 1.5% for women aged 45 years and above [5, 6]. Similarly, older women who conceived with their own eggs have a high risk of miscarriage, ranging from 33% at 40 years of age and increased to almost 100% by age 45 [7–9]. These miscarriages are attributed mainly to embryonic aneuploidy [7–9]. Even with normal ovarian reserve, embryos generated from older women have a low pregnancy potential [10]. Numerous studies have demonstrated that the female age is the most important factor in predicting IVF success [11, 12].

The effect of paternal age on reproduction is still not well understood. While, there is evidence that advanced paternal age increases chromosomal abnormalities [13], especially beyond the age of 50 [14]. Other studies found that there is insufficient evidence to demonstrate an unfavorable effect of paternal age [15].

Finding predictors of a positive outcome in women of advanced maternal age undergoing IVF is central to achieving success in ART. In this study, we aimed to determine the predictors for positive clinical outcomes in women over 40 undergoing IVF.

2. Materials and methods

This is a retrospective cohort study. Data was collected from patient charts. The inclusion criteria used included all females aged 40–46 years old going through IVF (In-Vitro Fertilization), with or without intra-cytoplasmic sperm injection (ICSI) cycles at the MCGill University Health Center Reproductive Center (A university affiliated reproductive center) from August 2010 to June 2012. All cycles during this time period were included with either cleavage or blastocyst transfer. Exclusion criteria were cycles where oocyte collection was not performed, oocyte donation or sperm donation cycles, and any intra-uterine pathology including submucosal fibroids or polyps that were not corrected pre-transfer. All subjects had normal serum TSH levels (0.4–2.5 IU/L), and prolactin per assay guidelines (on 1 out of 2 specimens). Couples requiring surgical sperm extraction or severe male factor
defined as less than 5 million total motile sperm count were also excluded. All subjects had a normal uterine cavity on imaging—without uterine anomalies, including septum, unicor-nuate or bicornuate uteri. None of the subjects had intramural fibroids without an intra-cavity component of more than 1.5 cm in maximum diameter, and these polyps and small fibroids were removed before inclusion in the study. None of the subjects were canceled for too few follicles developing. Even subjects with a single follicle were continued to the collection. If no embryos developed or no oocytes were collected (less than 5% of subjects), they could not be included in the analysis because a lack of embryos would have dropped that subject from the analysis by stepwise logistic regression. None of the subjects had evidence of endometriosis or hydrosalpinx. All subjects had a diagnosis of advanced maternal age causing infertility. None of the subjects had anovulation or thin endometrium at the time of transfer. The stimulation protocol and doses of gonadotropins were prescribed on a case-by-case basis according to patient basic characteristics and clinician preferences. The starting dose of gonadotropin was individualized for each patient based on age, basal FSH (Follicular stimulating hormone) levels, AFC (Antral follicular count), body mass index (BMI), and previous response to ovarian stimulation. Adjustment of the dose was performed according to the ovarian response, which was monitored by vaginal scans and estradiol (E2) determinations.

All treatments were conducted as previously described [16]. Ovarian stimulation was performed by one of the following protocols: the majority were treated with the microdose-flare protocol (491 cycles) [17]. The rest were treated with either a fixed GnRH (Gonadotropin-releasing hormone) antagonist protocol (332 cycles) [18] or the GnRH-ag long protocol (81 cycles) [19]. Once the primary follicle had an average diameter > 17 mm, hCG (human Chorionic Gonadotropin) was administered.

Oocyte retrieval was performed 36-hours after hCG triggering. All visible follicles, regardless of diameter, were aspirated. Fertilization of retrieved oocytes was carried out by IVF or ICSI. All embryos were cultured in cleavage medium (Cook Medical, Sydney, Australia) until day 3 and graded as previously described [20], and subsequently transferred to blastocyst medium (Cook Medical, Sydney, Australia) for culture to the blastocyst stage and then graded as previously described by Gardner et al. [21].

Fertilization support was given by Estradiol (Estradiol Valerate, Actavis Pharma, USA) 2 mg orally three times daily and progestin supplements (Prometrium 200 mg vaginally, three times daily, Merck Germany; Endometrin 200 mg vaginally, twice daily, Ferring USA; Crinone 8% vaginally twice daily, Actavis USA or intramuscular progesterone 100 mg daily, Actavis USA) were started on the day after oocyte collection and continued until 12 weeks of pregnancy.

Embryo transfer was performed on day 2, day 3, or day 5, based on embryo quality, a prior history of failed IVF cycles, and the number of embryos available for transfer. Three embryos were the maximum number allowed to be transferred, based on the Quebec regulatory law. The quality of the embryos was assessed morphologically, based on previous publications [22, 23]. Ultrasound-guided trans-cervical embryo transfer was performed using a Wallace catheter (Smiths Medical, USA) under transabdominal ultrasound guidance, with a full urinary bladder. None of the patients had embryos to vitrify.

A positive pregnancy test was defined as a serum β-hCG level of > 10 IU/L, measured 16 days after oocyte retrieval. Clinical pregnancy was defined as a pregnancy with an intrauterine gestational sac at six weeks gestational age on transvaginal ultrasound. Live birth was defined as a child born alive after 24 weeks of gestational age.

An analysis of a retrospectively collected dataset, which consisted of 631 women who underwent a total of 904 IVF cycles from August 2010 to June 2012, was performed. Only cycles resulting in fresh embryo transfer with autologous oocytes and sperm were included. The following variables were analyzed: maternal & paternal age, number of IVF cycle, treatment protocol, number of follicles less, or at least 14 mm on the day of trigger, number of oocyte(s) retrieved, viable oocytes, metaphase two (MII) oocyte(s), two pronuclei (2PN) embryo(s) number, number of cells and grade of the embryo(s) transferred. Patients were classified based on achieving a pregnancy, clinical pregnancy, and live birth.

Approval from the Research Ethics Board was obtained (IRB#13-053-SDR). Statistical analysis was done using SPSS 11-0, (Chicago, IL) with stepwise logistic regression analysis. This analysis was performed based on cycle outcome, obtained from an embryology database at a University-affiliated fertility center. Stepwise logistic regression analysis was performed on both continuous and categorical variables, which permitted to control for multiplicity and confounding effects between the data. The analysis was performed with the variables, not with the equation method. Only the grade and number of cells of the best embryo was used to perform the analysis. This was done because cases with missing data are not included in the analysis, by the program. Therefore, if the information on the second or third embryo transferred were included in the calculations, any subject with less transferred embryos would have been excluded from the analysis. An interaction term was introduced to compare the effect of male age on the live birth rate in women less than or greater than 40 years of age, using stepwise logistic regression. Data are presented as mean ± SD and confidence intervals.

3. Results
A total of 631 women over 40 years attempted IVF/ICSI cycles resulting in 904 autologous embryo transfers. According to the patients’ age at the start of treatment, there were 233, 245, 219, 127, 62, 16, and 2 cycles performed for women
at 40, 41, 42, 43, 44, and 46 years old, respectively. Two hundred and fourteen women (33.9%) had more than one IVF cycle. The mean number (± SD) of embryos transferred on the first cycle was 1.9 ± 0.68 embryos, second cycle 1.8 ± 0.67 embryos, third cycle 2.0 ± 0.72 embryos, and fourth cycle 2.1 ± 0.75. Fertilization was achieved by ICSI in 729 cycles (80.6%), conventional IVF in 168 cycles (18.6), and a combination of both (50% ICSI, 50% IVF) in seven cycles (0.8%). Outcomes as a function of maternal age are presented in Fig. 1. The overall pregnancy rate was 18.8% (170/904), the clinical pregnancy rate was 13.9% (126/904) and the LBR was 7.4% (67/904) per cycle.

Predictors of pregnancy as determined by stepwise binomial regression analysis are presented in Table 1. As expected, maternal age was a predictor of pregnancy. However, the other significant predictors of pregnancy were: number of follicles stimulated, number of oocytes collected, number of resulting embryos, grade of best embryo transferred, and day of embryo transfer. The group with a higher percentage of blastocysts transfers, when compared to the cleavage stage, was more likely to conceive. It should also be highlighted that paternal age, the previous number of IVF attempts, and stimulation protocol used were not predictors of pregnancy in this group.

Predictors of clinical pregnancy are presented in Table 2. These predictors were very similar to the predictors of pregnancy. Although, it should be noted that the grade of the embryo transferred and percent of blastocyst transfers, were no longer significant predictors of clinical pregnancy.

Predictors of live birth are presented in Table 3. Most predictors were similar to those presented in the other two previously presented tables (one and two), with those predictors related to a more vigorous number of follicles stimulated and maternal age remaining important. However, it should be highlighted that paternal age became an important predictor of live birth in this age group. The male age range was 25 to 73 years, with 95% falling below 53 years and the median was 41 years. However, when it comes to live birth, the number of embryos transferred and the number of cells in

Table 1. Predictors of pregnancy in women at least 40 years of age.

| Predictor                              | Conceived (n = 170) | Not Conceived (n = 734) | P-value | CI         |
|----------------------------------------|--------------------|------------------------|---------|------------|
| Maternal Age (Years)                   | 41.2 ± 1.2         | 41.6 ± 1.3             | 0.01    | 0.58–0.92  |
| Paternal Age (Years)                   | 43.3 ± 5.9         | 43.4 ± 6.4             | 0.81    | NS         |
| Protocol Used                          | 47% MDF            | 56% MDF                | NS      |            |
| Attempt number                         | 2.0 ± 1.6          | 2.1 ± 1.4              | 0.58    | NS         |
| Follicles < 14 mm                      | 6.2 ± 6.9          | 4.5 ± 4.3              | 0.05    | 1.01–3.8   |
| Follicles ≥ 14 mm                      | 5.3 ± 3.4          | 4.2 ± 2.9              | 0.004   | 1.3–2.9    |
| Oocytes Collected                      | 9.1 ± 6.1          | 6.5 ± 4.7              | 0.0001  | 1.7–2.6    |
| Viable Oocytes                         | 9.0 ± 6.2          | 6.5 ± 4.7              | 0.0001  | 1.4–2.4    |
| MII Oocytes                            | 7.0 ± 4.5          | 4.8 ± 3.7              | 0.0001  | 2.0–2.9    |
| 2PN Embryos                            | 5.0 ± 3.3          | 3.3 ± 2.8              | 0.0001  | 1.9–3.0    |
| Cleavage Stage Embryos                 | 4.9 ± 3.3          | 3.2 ± 2.8              | 0.0001  | 1.7–2.5    |
| Number of Embryos Transferred          | 2.0 ± 0.7          | 1.9 ± 0.7              | 0.004   | 1.1–2.0    |
| Number cells of best embryo transferred| 5.5 ± 2.2          | 4.6 ± 2.0              | 0.001   | 1.6–2.4    |
| Grade best Embryo Transferred          | 82% grade 2        | 65% grade 2            | 0.01    | 0.37–0.95  |
|                                        | 18% grade 3        | 33% grade 3            |         |            |
|                                        | 3% grade 4         |                        |         |            |
| Day of Transfer                        | 40% day 2          | 66% day 2              | 0.008   | 1.5–2.7    |
|                                        | 26% day 3          | 22% day 3              |         |            |
|                                        | 4% day 4           | 2% day 4               |         |            |
|                                        | 29% day 5          | 11% day 5              |         |            |

CI, Confidence interval; MII, Metaphase II; MDF, Micro-dose flare protocol; ANT, GnRH antagonist protocol; LONG, Long protocol; NS, Not significant.
Table 2. Predictors of clinical pregnancy in women at least 40 years of age.

| Predictor                          | Clinical Pregnancy (n = 126) | No Clinical Pregnancy (n = 778) | P-value | CI          |
|------------------------------------|-------------------------------|---------------------------------|---------|-------------|
| Maternal Age (Years)               | 41.1 ± 1.1                    | 41.6 ± 1.3                      | 0.001   | 0.50–0.89   |
| Paternal Age (Years)               | 42.9 ± 5.4                    | 43.4 ± 6.5                      | 0.67    | NS          |
| Protocol Used                      | 47% MDF                       | 55% MDF                         |         |             |
| Attempt number                      | 2.0 ± 1.5                     | 2.1 ± 1.4                       | 0.34    | NS          |
| Follicles < 14 mm                  | 6.8 ± 7.6                     | 4.5 ± 4.2                       | 0.012   | 1.3–3.2     |
| Follicles ≥ 14 mm                  | 5.4 ± 3.4                     | 4.3 ± 3.0                       | 0.005   | 1.6–2.7     |
| Oocytes Collected                  | 9.3 ± 6.3                     | 6.6 ± 4.7                       | 0.0001  | 1.7–2.5     |
| Viable Oocytes                    | 9.0 ± 6.4                     | 6.7 ± 4.8                       | 0.0001  | 1.3–2.1     |
| MIIOocytes                          | 7.2 ± 4.5                     | 4.9 ± 3.7                       | 0.0001  | 1.9–2.9     |
| 2PN Embryos                        | 5.2 ± 3.5                     | 3.3 ± 2.8                       | 0.0001  | 1.6–2.4     |
| Cleavage Stage Embryos             | 5.2 ± 3.5                     | 3.2 ± 2.8                       | 0.0001  | 1.8–2.2     |
| Number of Embryos Transferred      | 2.0 ± 0.7                     | 1.9 ± 0.7                       | 0.012   | 1.1–2.9     |
| Number cells of best embryo transferred | 5.6 ± 2.2                  | 4.6 ± 2.0                       | 0.009   | 1.4–2.6     |
| Grade best Embryo Transferred      | 80% grade 2                   | 66% grade 2                     | 0.17    | NS          |
| Day of Transfer                   | 39% day 2                     | 64% day 2                       | 0.29    | NS          |
|                                   | 27% day 3                     | 22% day 3                       |         |             |
|                                   | 5% day 4                      | 2% day 4                        |         |             |
|                                   | 30% day 5                     | 12% day 5                       |         |             |

CI, Confidence interval; MI, Metaphase II; MDF, Micro-dose flare protocol; ANT, GnRH antagonist protocol; LONG, Long protocol; 2PN, 2Pronuclei; NS, Not significant.

the best embryo transferred were no longer significant predictors. Interestingly, even though a greater percentage of patients with a live birth had a blastocyst transfer as compared to the clinical pregnancy and pregnancy groups, when controlling for confounding effects this was no longer a predictor of live birth.

To determine whether the finding of male age as a significant predictor of live birth was specific to our clinic’s patient population, a control group of 1292 IVF cycles among women less than 40 years of age, was collected during the same time period as the other women above 40 years of age. The analysis for live birth in this population was repeated (using multivariate logistic regression). Male age was not a significant predictor of live birth among women less than 40 years of age (P = 0.42). We subsequently performed an interaction on male age, female age grouping (less than 40 or greater than 40 years) for live birth using the logistic regression analysis. This interaction component was statistically significant (P = 0.01), suggesting that women at least 40 years of age behave differently than do women less than 40 years of age in response to the male age as a predictor of live birth. Interactions between the other factors measured were not significant, which demonstrated that women under 40 vs. 40 years of age and above responded in similar manners to maternal age, number of follicles stimulated, number of oocytes collected, number of resulting embryos, grade of best embryo transferred, and day of embryo transfer, the previous number of IVF attempts and stimulation protocol used. This means that among women less than 40 years of age, maternal age, number of follicles stimulated, number of oocytes collected, number of resulting embryos, and day of embryo transfer were all significant predictors of live birth (P < 0.05, in all cases). However, the previous number of IVF attempts, the stimulation protocol used, the number of embryos transferred, and the grade of best embryo transferred were not predictors of live birth in this younger sample of patients (P > 0.05). It should be noted that in this population more than 95% of patients had a single embryo transfer due to the Quebec embryo transfer guidelines, and more than 85% has an ideal grade embryo to transfer.

4. Discussion

This study was performed to fill the current gap in knowledge on stimulation and laboratory predictors of a positive clinical outcome in women at least 40 years of age being treated with IVF. Our data confirmed that maternal age is an important predictor of pregnancy, clinical pregnancy, and live birth [24–26], as is an improved ovarian stimulation. However, in women at 40 years of age, male partners age was found to be a predictor of live birth.

Another finding was that paternal age was a significant predictor of live birth in this age group of women. The effect of advanced paternal age on reproductive outcomes has not been clear in all studies. Several publications have
Table 3. Predictors of live birth in women at least 40 years of age.

|                          | Live birth (n = 67) | No Live birth (n = 837) | P-value | CI          |
|--------------------------|---------------------|-------------------------|---------|-------------|
| Maternal Age (Years)     | 41.0 ± 1.0          | 41.6 ± 1.3              | 0.002   | 0.36–0.78   |
| Paternal Age (Years)     | 42.1 ± 5.9          | 43.5 ± 6.4              | 0.04    | 0.62–0.94   |
| Protocol Used            | 43%MDF              | 55%MDF                  |         |             |
| Attempt number           | 2.0 ± 1.7           | 2.1 ± 1.4               | 0.5     | NS          |
| Follicles < 14 mm        | 7.8 ± 7.5           | 4.6 ± 4.6               | 0.03    | 1.1–3.4     |
| Follicles ≥ 14 mm        | 5.9 ± 3.6           | 4.3 ± 3.0               | 0.03    | 1.2–3.2     |
| Oocytes Collected        | 10.2 ± 7.0          | 6.7 ± 4.8               | 0.005   | 1.3–2.9     |
| Viable Oocytes           | 10.2 ± 7.4          | 6.7 ± 4.8               | 0.005   | 1.2–2.8     |
| MIIOocytes               | 8.0 ± 5.0           | 5.0 ± 3.7               | 0.001   | 1.3–2.4     |
| 2PN Embryos              | 5.7 ± 3.6           | 3.4 ± 2.9               | 0.0001  | 1.8–2.6     |
| Cleavage Stage Embryos   | 5.7 ± 3.7           | 3.4 ± 2.9               |         |             |
| Number of Embryos Transferred | 2.0 ± 0.7        | 1.9 ± 0.7               | 0.07    | NS          |
| Number cells of best embryo transferred | 5.4 ± 2.3 | 4.7 ± 2.0 | 0.30 | NS          |
| Grade best Embryo Transferred | 88% grade 2 | 66% grade 2 | 0.10 | NS          |
| Day of Transfer          | 37% day 2           | 63% day 2               | 0.29    | NS          |
|                          | 24% day 3           | 23% day 3               |         |             |
|                          | 1% day 4            | 2% day 4                |         |             |
|                          | 37% day 5           | 12% day 5               |         |             |

CI, Confidence interval; MII, Metaphase II; MDF, Micro-dose flare protocol; ANT, GnRH antagonist protocol; LONG, Long protocol; 2PN, 2 Pronuclei.

shown that advanced male age was found to be associated with increased risk of infertility [27], decrease in blastocyst formation [28], increased risk of miscarriage among women of different age groups, increased risk of fetal death [29], schizophrenia [30, 31] bipolar disorders [32], autism spectrum and attention deficit disorders as well as autosomal dominant diseases [33]. As opposed to the above, other studies shows that increased paternal age has no effect on implantation rate and pregnancy outcomes in IVF cycles nor significantly affect IVF/ICSI outcome in oocyte donation (OD) cycles [34–37]. It was hypothesized that these findings reflect male genomic activation within the embryo [1, 15, 27, 38–44].

There is no clear definition of advanced paternal age for reproduction [45]. Nonetheless, the significant impact of paternal age on live birth rates noted in this study may dictate a different approach to the advanced paternal age phenomenon that parallels advanced maternal age. Therefore, in couples where the woman is at least 40 years old, they should undergo counseling about the implications of male age on the likelihood of live birth. Accordingly, it would seem logical that when selecting donor sperm, women above the age of 40 years should use male age as selection criteria, as younger woman’s oocytes may be able to repair defects in the sperm of older men. This ability may be lost in women at least 40 years of age. However, another publication claims that until the age of 45 years, the sperm donor age does not affect pregnancy rate [36], which is in contrast with what we found. Clearly, female age may play a role in the effect of male age on pregnancy outcomes with IVF.

In line with other studies, a greater number of follicles, oocytes collected, viable oocyte, more mature oocytes, and particularly the number of embryos available for transfer, were statistically significant predictors of clinical pregnancy and live birth [46]; in fact, they were more important than maternal age in this age group. This is likely due to the relatively small age range involved and the more vigorous stimulation, resulting in a positive outcome. The fact that better stimulation and collection performance improves LBR, might be explained by a better chance of getting the euploid embryo. Based on a previous publication, given the low oocyte to live birth rate during ART, which decreases with female age, achieving more follicles, oocytes and embryos might explain the increased LBR [47]. This might be compensated in multiple IVF cycles by creating a bank of embryos or by preimplantation genetic screening (PGD).

The influence of the number of embryos transferred on clinical outcomes remains to be identified, but few studies have focused on the predictive value of the number of embryos available in patients aged > 40 years [48]. On the contrary to previous studies [46, 49], we found that the number of embryos available for transfer was a better predictor of clinical pregnancy than maternal age alone. In fact, in cycles yielding (5.7 ± 3.6 vs. 3.4 ± 2.9) two PN embryos, developing
into (5.7 ± 3.7 vs. 3.4 ± 2.9) cleavage stage embryos respectively, there was a statistically significant difference in live-birth rates, concluding that among other factors, the number of embryos yielded is a substantial determinant of success [46]. Numerous studies demonstrated that even in morphologically normal embryos, aneuploid rates are elevated with advanced maternal age [49–52]. This is likely why embryo grade and increased likelihood of a blastocyst transfer failed to be predictors of clinical pregnancy or live birth, even though they were predictors of pregnancy.

As expected, stimulation protocol was not a predictor of pregnancy, clinical pregnancy, or live birth and the data remains inconsistent on the superiority of one protocol over the other, in this age group [53–56].

A practical implication of this study is relevant for women who want to conceive from sperm donation. The findings of this study imply that the LBR might be higher if one chose a younger donor. Few studies have addressed the role of male age on pregnancy outcomes although this literature is expanding and is relatively consistent. However larger prospective studies would help validate results.

The strengths of this study are that it confirms the role of male age and other factors on outcomes in older women undergoing IVF. It also demonstrates that this role is related to older oocytes and loses importance when younger women have children with males of older age. Another strength is that all subjects had a uniform diagnosis of advanced maternal age. None of the subjects had a severe male factor, tubal factor, endometriosis, anovulation, or a uterine factor. Lastly, the inclusion of live birth data is another strength. It should be noted form cycles from 2012 live birth data only became available at the end of 2015. The data then had to be collected analyzed and written which is why the collection period is long ago. This is an inherent drawback to live birth data.

Likewise, the limitations of this study are numerous and worth mentioning. This is a retrospective and single-center study, which may mask undetected bias. Another limitation includes the analysis of these cycles without other factors that might affect outcomes, including duration and type (primary or secondary) of infertility, and lifestyle habits, as well as ovarian reserve tests. This study reflects the role of patient age and stimulation on outcomes. Unfortunately, anti-mullerian hormone (AMH) levels were not routinely drawn on patients at this time period in our clinic.

It should be noted that there is no habile method to obtain a power analysis for multivariate logistic regression analysis. However, this was a study of over 900 IVF cycles and as such the data is robust and well powered.

5. Conclusions

As expected, live birth was related to maternal age, improved ovarian stimulation, and embryo yield. Male age was also noted to be a significant individual predictor of live birth at a relatively young mean paternal age (42.1 ± 5.9 vs. 43.5 ± 6.4 years) (Table 1). Suggesting in women 40 years of age or greater, a male age of 43 years may effect the probability of live birth. Follicles ≥ 14 mm, the number of oocytes collected, the number of 2PN were also predictive of LBR. This finding may have implications in counseling older women towards IVF success.

Author contributions

GS, NMA and MHD were responsible for the study design, data collection, statistical analyses, and manuscript writing. JB and AVP were involved in the study design, or statistical analysis, and manuscript review. WYS analyzed the samples and reviewed the manuscript. MHD acted as a senior/consulting author.

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments.

Acknowledgment

Thank S. Yehuda Dahan for assistance with this article.

Funding

This research received no external funding.

Conflict of interest

The authors declare no conflicts of interest. The authors also declare that they have had full control of all primary data and that they agree to allow the Journal to review their data if requested.

References

[1] Serour G, Mansour R, Serour A, Abouighar M, Amin Y, Kamal O, et al. Analysis of 2,386 consecutive cycles of in vitro fertilization or intracytoplasmic sperm injection using autologous oocytes in women aged 40 years and above. Fertility and Sterility. 2010; 94: 1707–1712.

[2] Klipstein S, Regan M, Ryley DA, Goldman MB, Alper MM, Rein- dollar RH. One last chance for pregnancy: a review of 2,705 in vitro fertilization cycles initiated in women age 40 years and above. Fertility and Sterility. 2005; 84: 435–445.

[3] Chandra A, Copen CE, Stephen EH. Infertility service use in the united states: data from the National Survey of Family Growth, 1982–2010. 1982. Available at: https://permanent.access.gpo.gov /gpo59356/nhsr073.pdf (Accessed: 03 March 2020).

[4] Centers for Disease Control. 2016 assisted reproductive technology-national summary report. 2016. Available at: https://www.cdc.gov/art/reportsv/ (Accessed: 03 March 2020).

[5] HFEA. Fertility treatment in 2013-trends and figures. 2013. Available at: https://www.hfea.gov.uk/media/2081/hfea-fertility-tre nds-2013.pdf (Accessed: 03 March 2020).

[6] Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, et al. The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary on ART terminology. 2009. Human Reproduction. 2009; 24: 2683–2687.
Bentov Y, Hannam T, Jurisica A, Esfandiari N, Casper RF. Coenzyme Q10 supplementation and oocyte aneuploidy in women undergoing IVF-ICSI treatment. Clinical Medicine Insights: Reproductive Health. 2014; 8: 31–36.

Franasiak JM, Forman EJ, Hong KH, Werner MD, Upham KM, Treff NR, et al. The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophoderm biopsies evaluated with comprehensive chromosomal screening. Fertility and Sterility. 2014; 101: 656–663.e1.

Yarali H, Bozdag G, Polat M, Esiner I, Tiras B. Intracytoplasmic sperm injection outcome of women over 35: an analysis of 668 cycles. Archives of Gynecology and Obstetrics. 2010; 281: 349–354.

Toner JP. Age = egg quality, FSH level = egg quantity. Fertility and Sterility. 2003; 79: 491.

Gordon JD, DiMattina M, Reh A, Botes A, Celia G, Payson M. Utilization and success rates of unstimulated in vitro fertilization in the United States: an analysis of the Society for Assisted Reproductive Technology database. Fertility and Sterility. 2013; 100: 392–395.

Spandorfer SD, Chung PH, Kligman J, Liu HC, Davis OK, Rosennwaks Z. An analysis of the effect of age on implantation rates. Journal of Assisted Reproduction and Genetics. 2000; 17: 303–306.

Brandt JS, Cruz Ithier MA, Rosen T, Ashkinadze E. Advanced paternal age, infertility, and reproductive risks: a review of the literature. Prenatal Diagnosis. 2019; 39: 81–87.

Garcia-Ferreyra J, Hilario R, Dueñas J. High percentages of embryos with 21, 18 or 13 trisomy are related to advanced paternal age in donor egg cycles. Journal Brasileiro de Reproducao Assistida. 2018; 22: 26–34.

Dain L, Auslander R, Dirnfeld M. The effect of paternal age on assisted reproduction outcome. Fertility and Sterility. 2011; 95: 1–8.

Dahan MH, Agdi M, Shehata F, Son W, Tan SL. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ova. European Journal of Obstetrics Gynecology and Reproductive Biology. 2014; 172: 70–73.

Kelly SM, Pirwany IR, Phillips SJ, Tan SL. Microdose gonadotrophin releasing hormone agonist (GnRH-a) flare protocol compared with standard long protocol GnRH-a for ovarian stimulation in patients undergoing in vitro fertilization. Fertility and Sterility. 2002; 78: 5234.

Seyhan A, Ata B, Polat M, Son W, Yarali H, Dahan MH. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Human Reproduction. 2013; 28: 2522–2528.

Tan S, Maconochie N, Doyle P, Campbell S, Balen A, Bekir J, et al. Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin. American Journal of Obstetrics and Gynecology. 1994; 171: 513–520.

Alpha Scientists in Reproductive Medicine, ESHRE Special Interest Group Embryology. Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Reproductive BioMedicine Online. 2011; 22: 632–646.

Gardner D, Schoolcraft W. In vitro culture of human blastocyst. In: Towards reproductive certainty: infertility and genetics beyond 1999 (pp. 375–388). Carnforth: Parthenon Press. 1999.

Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertility and Sterility. 2000; 73: 1155–1158.

Moon JH, Son W, Henderson S, Mahfoudh A, Dahan M, Holzer H. Spindle examination in unfertilized eggs using the polarization microscope can assist rescue ICSI. Reproductive BioMedicine Online. 2011; 26: 280–283.

Cheung C, Chen C, Chao K, Chen S, Ho H, Yang YU. Age is a better predictor of pregnancy potential than basal follicle-stimulating hormone levels in women undergoing in vitro fertilization. Fertility and Sterility. 2003; 79: 63–68.

Terriou P, Sapin C, Giorgetti C, Hans E, Spach J, Roulier R. Embryo score is a better predictor of pregnancy than the number of transferred embryos or female age. Fertility and Sterility. 2001; 75: 525–531.

Timeva T, Milachitch T, Petkova L, Barov D, Shterev A. Assessment of the woman's age as a main predictive factor of assisted reproductive technology treatment outcome. Akusherstvo i Ginekolinia. 2006; 45: 22–27. (In Bulgarian)

de La Rochebrochard E, de Mouzon J, Thépot F, Thonneau P. Fathers over 40 and increased failure to conceive: the lessons of in vitro fertilization in France association. Fertility and Sterility. 2006; 85: 1420–1424.

Mazzilli R, Cinamodo D, Vaiarelli A, Capalbo A, Dovere L, Alviggi E, et al. Effect of the male factor on the clinical outcome of intracytoplasmic sperm injection combined with preimplantation aneuploidy testing: observational longitudinal cohort study of 1,219 consecutive cycles. Fertility and Sterility. 2017; 108: 961–972.e3.

Nybo Andersen A, Urhoj SK. Is advanced paternal age a health risk for the offspring? Fertility and Sterility. 2017; 107: 312–318.

D’Onofrio BM, Rickert ME, Frans E, Kuja-Halkola R, Almqvist C, Terriou P, Sapin C, Giorgetti C, Hans E, Spach J, Roulier R. Embryo score is a better predictor of pregnancy than the number of transferred embryos or female age. Fertility and Sterility. 2003; 79: 63–68.

Whelan EC, Nwala AC, Osoogd C, Olarius S. Selective mutation accumulation: a computational model of the paternal age effect. Bioinformatics. 2016; 32: 3790–3797.

Bellver J, Garrido N, Remohi J, Pellicer A, Meseguer M. Influence of paternal age on assisted reproduction outcome. Reproductive BioMedicine Online. 2008; 17: 595–604.

Capelouto SM, Nagy ZP, Shapiro DB, Archer SR, Ellis DP, Smith AK, et al. Impact of male partner characteristics and semen parameters on in vitro fertilization and obstetric outcomes in a frozen oocyte donor model. Fertility and Sterility. 2018; 110: 859–869.

Ghuman NK, Mair E, Pearce K, Choudhary M. Does age of the sperm donor influence live birth in assisted reproduction? Human Reproduction. 2016; 31: 582–590.

Wu Y, Kang X, Zheng H, Liu H, Huang Q, Liu J. Effect of paternal age on reproductive outcomes of intracytoplasmic sperm injection. PLoS ONE. 2016; 11: e0149867.

Ciray HA, Ulug U, Tosun S, Erden HF, Bahceci M. Outcome of 1114 ICSI and embryo transfer cycles of women 40 years of age and over. Reproductive Biomedicine Online. 2006; 13: 516–522.

Ferreira RC, de Almeida Ferreira Braga DP, de Souza Bonetti TC, Pasqualotto FF, Iaconelli A, Borges E. Negative influence of paternal age on assisted reproductive technology treatment outcome. Fertility and Sterility. 2010; 93: 1870–1874.

Frattarelli JL, Miller KA, Miller BT, Elkind-Hirsch K, Scott RT. Male age negatively impacts embryo development and reproductive outcome in donor oocyte assisted reproductive technology cycles. Fertility and Sterility. 2008; 90: 97.

Gallardo E, Simó C, Levy M, Guannes PP, Remohi J, Pellicer A. Effect of age on sperm fertility potential: oocyte donation as a model. Fertility and Sterility. 1996; 66: 260–264.
